Literature DB >> 7204487

Inhibition of fusion of embryonic muscle cells in culture by tunicamycin is prevented by leupeptin.

K Olden, J Law, V A Hunter, R Romain, J B Parent.   

Abstract

The carbohydrate requirement for alignment and fusion of embryonic quail muscle cells has been examined in tissue culture by use of tunicamycin (TM). The mononucleated, spindle-shaped proliferating myoblasts were treated with TM at various times before fusion and differentiation into multinucleated muscle fibers capable of spontaneous contraction. Tm blocked protein glycosylation and expression of glycoproteins on the cell surface, and strongly inhibited fusion when added to cultures of differentiating muscle cells before the fusion "burst," but had no apparent effect on cell alignment. The inhibition of fusion was partially prevented when TM was administered in the presence of protease inhibitors such as leupeptin and pepstatin, but the inhibition of glycosylation was not prevented. Both glycosylation and fusion were completely restored to normal by the removal of the antibiotic from the medium. These studies provide strong support for the idea that myoblast fusion is partially mediated by glycoproteins with asparagine-linked oligosaccharides. However, the requirement for the carbohydrate portion of the glycoprotein appears to be indirect in that it acts to stabilize the protein moiety against proteolytic degradation. Our findings do not rule out the possibility that oligosaccharide units of surface glycolipids have some role in myoblast fusion.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7204487      PMCID: PMC2111718          DOI: 10.1083/jcb.88.1.199

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  37 in total

1.  Evidence that a membrane bound lectin mediates fusion of L6 myoblasts.

Authors:  T K Gartner; T R Podleski
Journal:  Biochem Biophys Res Commun       Date:  1975-12-01       Impact factor: 3.575

2.  A hepatic receptor of avian origin capable of binding specifically modified glycoproteins.

Authors:  J Lunney; G Ashwell
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

3.  Tunicamycin inhibition of polyisoprenyl N-acetylglucosaminyl pyrophosphate formation in calf-liver microsomes.

Authors:  J S Tkacz; O Lampen
Journal:  Biochem Biophys Res Commun       Date:  1975-07-08       Impact factor: 3.575

4.  Mutants of Balb/c 3T3 fibroblasts defective in adhesiveness to substratum: evidence for alteration in cell surface proteins.

Authors:  J M Pouysségur; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

5.  Delayed degeneration of dystrophic and normal muscle cell cultures treated with pepstatin, leupeptin, and antipain.

Authors:  E B McGowan; S A Shafiq; A Stracher
Journal:  Exp Neurol       Date:  1976-03       Impact factor: 5.330

6.  Diffusion-mediated control of myoblast fusion.

Authors:  I R Konigsberg
Journal:  Dev Biol       Date:  1971-09       Impact factor: 3.582

7.  Lack of evidence for the involvement of a beta-D-galactosyl-specific lectin in the fusion of chick myoblasts.

Authors:  H Den; D A Malinzak; A Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-04-05       Impact factor: 3.575

Review 8.  Inherited disorders of lysosomal metabolism.

Authors:  E F Neufeld; T W Lim; L J Shapiro
Journal:  Annu Rev Biochem       Date:  1975       Impact factor: 23.643

9.  Tunicamycin inhibition of (3H) glucosamine incorporation into yeast glycoproteins: binding of tunicamycin and interaction with phospholipids.

Authors:  S C Kuo; O Lampen
Journal:  Arch Biochem Biophys       Date:  1976-02       Impact factor: 4.013

10.  Inhibition of glycosylation of the influenza virus hemagglutinin.

Authors:  R T Schwarz; H D Klenk
Journal:  J Virol       Date:  1974-11       Impact factor: 5.103

View more
  12 in total

Review 1.  The fusion of myoblasts.

Authors:  M J Wakelam
Journal:  Biochem J       Date:  1985-05-15       Impact factor: 3.857

2.  Correlation between fusion and the developmental regulation of membrane glycoproteins in L6 myoblasts.

Authors:  J Rosenberg; A Szabo; D Rheuark; C Kayalar
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

3.  Developmental regulation of neuraminidase-sensitive lectin-binding glycoproteins during myogenesis of rat L6 myoblasts.

Authors:  P C Holland; S D Pena; C W Guerin
Journal:  Biochem J       Date:  1984-03-01       Impact factor: 3.857

4.  The calcitonin receptor on T 47D breast cancer cells. Evidence for glycosylation.

Authors:  J M Moseley; D M Findlay; J J Gorman; V P Michelangeli; T J Martin
Journal:  Biochem J       Date:  1983-06-15       Impact factor: 3.857

5.  Isolation and characterization of rat skeletal myoblast mutants resistant to lectins.

Authors:  B Gilfix; J Rogers; B D Sanwal
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

6.  Glycogenome expression dynamics during mouse C2C12 myoblast differentiation suggests a sequential reorganization of membrane glycoconjugates.

Authors:  Mathilde Janot; Aymeric Audfray; Céline Loriol; Agnès Germot; Abderrahman Maftah; Fabrice Dupuy
Journal:  BMC Genomics       Date:  2009-10-20       Impact factor: 3.969

7.  Response of malignant and nonmalignant epidermal cell lines to tunicamycin.

Authors:  M M Brysk; J Miller; S J Chen; P C Moller; R W Stach
Journal:  Cell Tissue Res       Date:  1986       Impact factor: 5.249

8.  Inhibition of myoblast fusion by the glucosidase inhibitor N-methyl-1-deoxynojirimycin, but not by the mannosidase inhibitor 1-deoxymannojirimycin.

Authors:  P C Holland; A Herscovics
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

9.  The calcium-dependent myoblast adhesion that precedes cell fusion is mediated by glycoproteins.

Authors:  K A Knudsen
Journal:  J Cell Biol       Date:  1985-09       Impact factor: 10.539

10.  Trifluoperazine, a calmodulin antagonist, inhibits muscle cell fusion.

Authors:  D Bar-Sagi; J Prives
Journal:  J Cell Biol       Date:  1983-11       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.